- Home
- ACB vs VYGR Comparison
ACB vs VYGR Comparison
Compare ACB & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACB
- VYGR
- Stock Information
- Founded
- ACB 2013
- VYGR 2013
- Country
- ACB Canada
- VYGR United States
- Employees
- ACB N/A
- VYGR N/A
- Industry
- ACB Pharmaceuticals and Biotechnology
- VYGR Biotechnology: Pharmaceutical Preparations
- Sector
- ACB Health Care
- VYGR Health Care
- Exchange
- ACB Nasdaq
- VYGR Nasdaq
- Market Cap
- ACB 256.5M
- VYGR 231.9M
- IPO Year
- ACB N/A
- VYGR 2015
- Fundamental
- Price
- ACB $5.27
- VYGR $4.67
- Analyst Decision
- ACB
- VYGR Strong Buy
- Analyst Count
- ACB 0
- VYGR 8
- Target Price
- ACB N/A
- VYGR $16.71
- AVG Volume (30 Days)
- ACB 2.5M
- VYGR 781.5K
- Earning Date
- ACB 11-05-2025
- VYGR 11-11-2025
- Dividend Yield
- ACB N/A
- VYGR N/A
- EPS Growth
- ACB N/A
- VYGR N/A
- EPS
- ACB N/A
- VYGR N/A
- Revenue
- ACB $262,403,032.00
- VYGR $42,580,000.00
- Revenue This Year
- ACB $9.42
- VYGR N/A
- Revenue Next Year
- ACB $5.72
- VYGR $107.10
- P/E Ratio
- ACB N/A
- VYGR N/A
- Revenue Growth
- ACB 28.58
- VYGR N/A
- 52 Week Low
- ACB $3.42
- VYGR $2.65
- 52 Week High
- ACB $6.91
- VYGR $7.44
- Technical
- Relative Strength Index (RSI)
- ACB 48.14
- VYGR 49.46
- Support Level
- ACB $4.90
- VYGR $4.52
- Resistance Level
- ACB $5.40
- VYGR $5.13
- Average True Range (ATR)
- ACB 0.37
- VYGR 0.35
- MACD
- ACB -0.08
- VYGR -0.09
- Stochastic Oscillator
- ACB 21.25
- VYGR 13.59
About ACB Aurora Cannabis Inc.
Aurora Cannabis Inc headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard. Although the company operates in Canada, it has expanded internationally through medical cannabis exporting agreements. The company opertes in Canada, Europe, Australia, and Others, with majority revenue from Canada.
About VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.